Sign In
Buy KDMN
$9.50
+0 (+0%)
At Close: Aug 17, 2022
COVID-19 Collaboration For Johnson & Johnson's Janssen Unit, And Other News: The Good, Bad And Ugly Of Biopharma
08:17pm, Sunday, 19'th Apr 2020
Janssen signed a collaboration with ImmunoPrecise Antibodies Ltd. Kadmon will file an NDA for its GVHD drug. Pfenex suffered a regulatory setback.
Is Kadmon Holdings, Inc. (NYSE:KDMN) Overpaying Its CEO?
01:20pm, Tuesday, 14'th Apr 2020
Harlan Waksal became the CEO of Kadmon Holdings, Inc. (NYSE:KDMN) in 2014. First, this article will compare CEO...
Kadmon Announces Receipt of Final Meeting Minutes from FDA Following Pre-NDA Meeting for KD025 for the Treatment of cGVHD
11:59am, Tuesday, 14'th Apr 2020
NEW YORK, NY / ACCESSWIRE / April 14, 2020 / Kadmon Holdings, Inc. (KDMN) today announced that it has received the final meeting minutes from the U.S. Food and Drug Administration (FDA) following its
Analysts Conflicted on These Healthcare Names: Arrowhead Pharmaceuticals (ARWR) and Kadmon Holdings (KDMN)
08:21pm, Wednesday, 18'th Mar 2020
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Arrowhead Pharmaceuticals (ARWR) and Kadmon Holdings
Analysts Conflicted on These Healthcare Names: Arrowhead Pharmaceuticals (NASDAQ: ARWR) and Kadmon Holdings (NYSE: KDMN)
08:21pm, Wednesday, 18'th Mar 2020
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Arrowhead Pharmaceuticals (ARWR
7 “Perfect 10” Healthcare Stocks to Buy Now
04:15pm, Wednesday, 18'th Mar 2020
Wall Street pros recommend making an investment decision based on multiple factors rather than just a single metric like fundamentals.
Kadmon Announces Update on pre-NDA Meeting with FDA and Provides Business Update
08:15pm, Friday, 13'th Mar 2020
NEW YORK, NY / ACCESSWIRE / March 13, 2020 / Kadmon Holdings, Inc. (NYSE: KDMN) today announced that the Company held its pre-New Drug Application (NDA) meeting as scheduled with the U.S. Food and Dru
Amneal Pharmaceuticals Appoints Tasos Konidaris as Senior Vice President, Chief Financial Officer
09:36pm, Wednesday, 11'th Mar 2020
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) ("Amneal" or the "Company") today announced it has appointed Tasos Konidaris as Senior Vice President, Chief Financial Officer, effective March 12, 2020. Mr.
Here's Why We're Not Too Worried About Kadmon Holdings's (NYSE:KDMN) Cash Burn Situation
05:57pm, Monday, 09'th Mar 2020
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysts Are Bullish on These Healthcare Stocks: Kadmon Holdings (KDMN), Outlook Therapeutics (OTLK)
11:09am, Monday, 09'th Mar 2020
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Kadmon Holdings (KDMN), Outlook Therapeutics (OTLK) and
Analysts Are Bullish on These Healthcare Stocks: Kadmon Holdings (KDMN), Outlook Therapeutics (OTLK)
11:09am, Monday, 09'th Mar 2020
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Kadmon Holdings
Kadmon Highlights Recent Progress and Reports Fourth Quarter and Full Year 2019 Financial Results
09:14pm, Thursday, 05'th Mar 2020
NEW YORK, March 05, 2020 -- Kadmon Holdings, Inc. (NYSE: KDMN) today provided a business update and reported financial and operational results for the fourth quarter and full.
Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO) and Esperion (ESPR)
11:15pm, Thursday, 27'th Feb 2020
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Allogene Therapeutics (ALLO) and Esperion (ESPR) with
Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (NASDAQ: ALLO) and Esperion (NASDAQ: ESPR)
11:15pm, Thursday, 27'th Feb 2020
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Allogene Therapeutics
Iovance Biotherapeutics (IOVA) Received its Third Buy in a Row
11:25am, Wednesday, 26'th Feb 2020
After Piper Sandler and Cowen & Co. gave Iovance Biotherapeutics (NASDAQ: IOVA) a Buy rating last month, the company received another Buy, this time
